EUVIMEDEUVIMED entdecken
Crossref

Carcinogenicity in the 21st Century: Data Interpretation—Session 4

Sandra De Jonghe iD, Matthew Jacobsen iD, Jim Saul iD, Alys Bradley iD, John R Foster iD, Zuhal Dincer, Ute Bach iD, Tanasa Osborne

Toxicologic Pathology · 2026-07 · 54 (5) · 391-393

DOI: 10.1177/01926233261435939 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicologic Pathology, online erschienen am 08.04.2026. Verfasst von Sandra De Jonghe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson Innovative Medicine, Beerse, Belgium. Hauptthemen laut MEDLINE: Carcinogens, Neoplasms. Die Arbeit nennt 3 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 2025 joint British Society of Toxicologic Pathology (BSTP) and European Society of Toxicologic Pathology (ESTP) Congress included a session on data interpretation, which can be complex and is a critical aspect of carcinogenicity studies. In addition to statistical analysis, consistency in nomenclature, high-quality peer review, the appropriate use of historical control data, knowledge on compound- and target-related information, and literature can contribute to high-quality data, optimal interpretation of biological relevance, and safety assessment. The speakers covered several of these aspects which are critical in data interpretation of carcinogenicity studies. Based on experience and case examples, recommendations for updating International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) terminology for some proliferative findings in exocrine pancreas, liver, and ovaries were presented, including a case example of human relevance and risk assessment of endocrine and reproductive system tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarcinogensNeoplasmsHumansCarcinogenicity TestsAnimalsData Interpretation, StatisticalRisk AssessmentFemaleTerminology as Topic

Stichwörter der Autor:innen

INHANDcarcinogenicitycombining tumorshistorical control data

Substanzen

Carcinogens

Autor:innen und Institutionen

  • Johnson & Johnson Innovative Medicine, Beerse, Belgium.
  • AstraZeneca, Cambridge, UK.
  • Labcorp, Harrogate, UK.
  • Charles River Laboratories, Edinburgh, UK.
  • ToxPath Sciences Ltd, Congleton, UK.
  • Sequani Ltd, Ledbury, UK.

ORCID-Profile: Sandra De Jonghe, Matthew Jacobsen, Jim Saul, Alys Bradley, John R Foster, Ute Bach

Zitieren

APA

De Jonghe, S., Jacobsen, M., Saul, J., Bradley, A., Foster, J. R., Dincer, Z., Bach, U., & Osborne, T. (2026). Carcinogenicity in the 21st Century: Data Interpretation—Session 4. Toxicologic Pathology, 54(5), 391-393. https://doi.org/10.1177/01926233261435939

Vancouver

De Jonghe S, Jacobsen M, Saul J, Bradley A, Foster JR, Dincer Z, et al. Carcinogenicity in the 21st Century: Data Interpretation—Session 4. Toxicologic Pathology. 2026;54(5):391-393. doi:10.1177/01926233261435939

BibTeX
@article{DeJonghe2026,
  author = {De Jonghe, Sandra and Jacobsen, Matthew and Saul, Jim and Bradley, Alys and Foster, John R and Dincer, Zuhal and Bach, Ute and Osborne, Tanasa},
  title = {Carcinogenicity in the 21st Century: Data Interpretation—Session 4},
  journal = {Toxicologic Pathology},
  year = {2026},
  volume = {54},
  number = {5},
  pages = {391--393},
  doi = {10.1177/01926233261435939}
}
Kostenlos starten →